WhiteOak Capital Mutual Fund launches thematic and sectoral NFOs: Should you invest in them?

White Oak Capital Mutual Fund on Tuesday, January 16, launched two new fund offers (NFOs). These are WhiteOak Capital Banking & Financial Services Fund and WhiteOak Capital Pharma and Healthcare Fund. Both the NFOs are open-ended in nature and will be available till January 30, 2024.

While the former is a scheme investing in the banking and financial services sector, the latter is an equity scheme investing in the pharma and healthcare sector.

The WhiteOak Capital Banking & Financial Services Fund falls under the Equity - Thematic Fund category. It aims to outperform the Nifty Financial Services Total Return Index (TRI), which serves as its benchmark.

The primary goal of the scheme is to achieve long-term capital appreciation for investors. The fund will focus on equity and equity-related instruments of companies within the financial services sector.

However, it is essential to note that, as with any investment, there is no absolute assurance that the investment objective of the scheme will be realised, the fund house said.

Investors in the fund will not incur any entry load.

However, an exit load of 1.00% is applicable for redemptions or switches within one month from the date of allotment.

After the first month, no exit load is levied.

Equity & Equity Related Instruments of Banks & Financial Services Companies: 80-100% (Very High Risk)

Equity & Equity Related Instruments of Companies Other Than Above 0-20% (Very High Risk)

Debt Securities and Money Market Instruments: 0-20% (Low to Medium Risk)

Units issued by REITs and InVITs: 0-10% (Very High Risk)

The WhiteOak Capital Banking & Financial Services Fund offers two plans - a Direct Plan and a Regular Plan. Investors can start their journey with the fund by subscribing with a minimum amount of ₹100, and subsequent investments can be made in multiples of ₹1.

The WhiteOak Capital Pharma & Healthcare Fund falls under the Sectoral Fund category, emphasising a concentrated approach to the pharmaceutical and healthcare segments.

The fund aims to outperform its benchmark, the S&P BSE Healthcare Total Return Index (TRI), reflecting the performance of the healthcare sector.

The primary objective of the scheme is to achieve long-term capital appreciation by predominantly investing in equity and equity-related instruments of Pharma and Healthcare companies.

However, it's crucial to note that, as with any investment, there is no absolute assurance that the investment objective of the scheme will be realised.

There is no entry load, making it accessible to a wide range of investors.

For exit loads, a 1.00% charge is applicable if units are redeemed or switched out within one month from the date of allotment. After the first month, no exit load is levied.

The minimum subscription amount required is ₹100, and subsequent investments can be made in multiples of ₹1.

Both the NFOs provide an entry point with a minimum subscription of ₹100, catering to a diverse range of investors.

However, investors must acknowledge the inherent uncertainties in all investments, and a thorough evaluation of risk factors is advisable before considering these NFOs for inclusion in their portfolios, experts say.